Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard M. Goldberg has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Highlights in Gastrointestinal (Colorectal) Cancer Treatment

    by Kristen K. Ciombor, Richard M. Goldberg

    Presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) unveiled several important and exciting findings for patients and oncologists engaged in the treatment of colorectal cancer (CRC). Novel results included the primary tumor sidedness data in CRC, as well as data from multiple immunotherapy studies for microsatellite-stable and -unstable CRC and anal cancer. The findings that right- and left-sided CRCs differ in prognosis and drug sensitivity was made more credible by consecutive presentations of data from a phase 3 trial, a single institution’s experience, and from the SEER registry. Alan Venook, MD, presented a retrospective ad hoc analysis of CALGB/SWOG 80405,1 examining the effect of primary tumor sidedness on patient outcomes by biologic treatment subgroups. The primary study results, previously presented as a plenary session ASCO abstract in 2014, showed that overall survival (OS) of patients with KRAS wild-type metastatic CRC (mCRC) treated in the first-line setting with either bevacizumab or cetuximab combined with FOLFOX or FOLFIRI was longer than anticipated but did not differ between treatments (32.0 months for the cetuximab group vs 31.2 months for the bevacizumab group). In this year’s presentation, data from colonoscopy reports, imaging, and operative notes were analyzed to determine left- (including rectal) vs right-sided primary tumor and the effect of sidedness on survival.


  • Open Access

    In Memoriam: A Tribute to Daniel J. Sargent, Ph.D.

    by Richard M. Goldberg


  • Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.

    by Christina Sing-Ying Wu, Qian Shi, Jerneja Tomsic, Jeffrey P. Meyers, Wendy L Frankel, Cynthia Dawn Timmers, Leonard Saltz, Steven R. Alberts, Donna Niedzwiecki, Daniel J. Sargent, et al.

    E15148 Background: MSI is detected in approximately 15% colorectal cancers, and associated with improved survival in early stage colon cancer. Heat shock protein 110 (HSP110) is a chaperone protein expressed in colon cancer and enhances cancer cell survival. Mutant HSP110, which is only present in MSI tumors, is due to deletions in a T17 mononucleotide repeat leading to synthesis of a truncated protein, and has a dominant negative effect on HSP110 function. Large T17 deletion size correlates with increased amount of mutant HSP110 transcript, and may be a biomarker for improved patient (pt) outcome. We correlated disease-free survival (DFS) with T17 deletion size in stage III MSI colon cancer pts who received adjuvant chemotherapy on CALGB 89803 or NCCTG N01477. Methods: Pts for this retrospective study were enrolled on CALGB 89803 or NCCTG N01477, had tissue for analysis, and were evaluable for DFS (primary endpoint). T17 deletion size was determined by PCR and fragment analysis. The pre-specified cut-off was 5 base pairs ( > 5 for large deletion, < 5 for small deletion), and stratified multivariate Cox PH regression models were performed to compare outcomes in the 2 groups. Results: A total of 414 samples were tested (104 from CALGB 89803 and 310 from NCCTG N0147) and 77 (19%) specimens failed testing. Of the 337 samples, 195 pts had large T17 deletions and 142 pts had small T17 deletions. Pt demographics, disease characteristics, and adjuvant treatment were comparable between the 2 groups. Large T17 deletion did not correlate with improved DFS, overall survival (OS), or time-to-recurrence (TTR). (Table) Conclusions: Large HSP110 T17 deletion size does not correlate with improved DFS in pts with Stage III MSI colon cancers.

  • Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

    by Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip Edward Lammers, Tanios S. Bekaii-Saab, et al.

    4003 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to doxorubicin plus sorafenib (D+S) showed a significant improvement in overall survival favoring D+S (JAMA, 2011). The results appeared promising compared to the historic outcomes seen in the pivotal sorafenib (S) trials. CALGB 80802 was designed to determine if D+S improved survival compared to S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were randomized to receive D 60 mg/m2 every 21 days plus S 400 mg PO twice daily (D+S) or S alone. For bilirubin ≥ 1.3x normal, D and S doses were halved. D was maxed out at 360 mg/m2. The study was stratified by extent of disease (locally advanced; metastatic), the primary endpoint was overall survival (OS); and secondary endpoint progression-free survival (PFS). The final analysis was to occur when 364 events were observed among 480 total patients, with 90% power to detect a 37% increase in median OS (10.7 to 14.7 months; 1-sided α = 0.05). Results: The Alliance DSMB halted the study after accrual of 346 patients (173 on each of D+S and S) when a futility boundary was crossed at a planned interim analysis. With 107 events in each arm, median OS was 9.3 months (95%CI 7.1-12.9) for D+S, and 10.5 months (95% CI 7.4-14.3) for S with a hazard ratio (HR) 1.06 (95% CI 0.8- 1.4) for D+S vs. S. Median PFS was 3.6 (95% CI 2.8-4.6) and 3.2 months (95% CI 2.3-4.1), respectively (HR = 0.90, 95% CI 0.72-1.2). There were 38 deaths on treatment: 18 on D+S and 20 on S. Among these 8 [sepsis (1), dysphagia (1), pneumonia (1), cardiac (2), hepatic failure (2), and not otherwise specified (1)] on D+S, and 3 [fatigue (1), hepatic failure (1), and a secondary malignancy (1)] on S, were at least possibly related to treatment. A maximum grade 3 or 4 only hematologic adverse events (AE) occurred in 37.8% of patients on D+S and 8.1% of patients on S. Non-hematologic AEs were comparable, in 63.6% and 61.5% of patients, respectively. Conclusions: The addition of D to S resulted in higher toxicity and did not improve OS or PFS. The S median OS of about 10 months is consistent with previous reports. NCI Grant U10CA180821 Clinical trial information: NCT01015833.


  • Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC).

    by Daniel H. Ahn, Chul Ahn, Apurva Jain, Sameh Mikhail, Christina Sing-Ying Wu, Richard M. Goldberg, Kristen Keon Ciombor, Anne M. Noonan, Priyanka Sadavartia, Rachna T. Shroff, et al.

    287 Background: aBTC is uncommon and has a dismal prognosis with limited therapeutic options. First-line therapy for untreated aBTC is GC, with no approved therapies in the refractory setting. To assess for tumor-specific genetic variants that affect outcomes in patients (pts) who received GC in aBTC, we performed NGS in pts treated with who received GC as first-line therapy. Methods: Archival formalin-fixed, paraffin-embedded samples from pts with mBTC from Ohio State University and MD Anderson Cancer Center who received GC in the first-line and underwent NGS as part of routine care. 315 cancer-related genes plus select introns from 28 genes altered in solid tumors were included in the NGS panel. Univariate Cox regression model was used to determine the association between gene mutations with progression free survival (PFS) and (OS). Results: 80 evaluable pts with aBTC treated with first-line GC chemotherapy underwent successful genomic profiling. A total of 414 cancer-specific mutations were identified, where 49 (12%) genes had mutations with > 5% frequency. 17 of the 49 were known mutations. From the comprehensive analysis, somatic mutations in IDH1 (11 of 80 pts; 13%) (HR 0.31; p = 0.035) was associated with improved overall survival (OS) and progression free survival (PFS). Pts wild type for IDH1 had a median OS of 17.7 months and PFS of 4.5 months, while those with an IDH1 mutation had a median OS that was not reached and an improved PFS of 5.7 months. Conclusions: Somatic mutations in IDH1 were associated with improved clinical outcomes in pts with aBTC who received GC as first-line therapy which is consistent with other solid tumor malignancies. IDH1 is a therapeutic target of interest, where future prospective studies will be necessary to validate the predictive utility and its relevance in pt outcomes in aBTC.

  • Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience.

    by Manojkumar Bupathi, Daniel H. Ahn, Kristen Keon Ciombor, Christina Sing-Ying Wu, Sameh Mikhail, Richard M. Goldberg, Anne M. Noonan, Julie Stephens, Josh Reardon, John L. Hays, et al.

    215 Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer with a very dismal prognosis. Recently, MM-398 (nanoliposomal irinotecan) was shown to be associated with significant improvement in progression free survival (PFS) and overall survival (OS) with acceptable toxicities when combined with 5-Fluorouracil (5FU)/ leucovorin (LV) compared to 5-FU/LV alone in patients failing one line of gemcitabine-based therapy. There is a paucity of data evaluating the role of irinotecan in combination with 5FU in APC. Methods: We performed a retrospective analysis of all patients who received mFOLFIRI (minus bolus 5FU and LV). All patients with metastatic disease who had failed at least one line of gemcitabine-based therapy prior to receiving mFOLFIRI were included in this study. Descriptive statistics were used to assess the continuous variables and adverse events (AEs) and Kaplan-Meier methods were used to calculate the median PFS and OS. Results: Forty patients were included in this analysis, 33% male. Patients had received 1 to 5 lines of prior therapy (27% with 1 prior and 25% with more than 3 lines of prior therapy). The mean age at diagnosis was 60 and 97% had ECOG of 1. The average CA 19-9 at the start of therapy was 33168 U/ml. The median PFS (from the start of FOLFIRI to disease progression or last follow up) was 2.59 months [95% confidence interval (CI); (1.90, 3.54)] and OS (from the start of FOLFIRI to death or least follow up) was 4.75 months [95% CI (3.14, 8.98)]. The most common AEs included fatigue (98%), neuropathy (83%), anorexia (68%), nausea (60%) and constipation (55%). Grade 3 toxicities included fatigue (13%) and rash (3%). There were no observed grade 4 toxicities that were observed. Conclusions: In this single institution retrospective analysis, mFOLFIRI was found to be both tolerable and relatively effective in this heavily pretreated patient population with APC. Future prospective studies should consider evaluating the role of mFOLFIRI in refractory APC.

  • PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

    by Dung T. Le, Jennifer N. Uram, Hao Wang, Holly Kemberling, Aleksandra Eyring, Bjarne Bartlett, Richard M. Goldberg, Todd S. Crocenzi, George A. Fisher, James J. Lee, et al.

    195 Background: Mismatch repair (MMR) deficient tumors harbor hundreds to thousands of mutations that may produce neoantigens that can be recognized and targeted by T cells. We have shown that MMR deficiency can serve as a predictive biomarker for selection of tumors across tumor histologies that may respond to programmed death-1 (PD-1) blockade. MMR deficiency is present in 15% of colorectal (CRC) however is also detected in 2-20% of gastric, small bowel, and hepatobiliary cancers. Methods: We conducted a phase II study to evaluate anti-PD-1, pembrolizumab, in patients with previously-treated, progressive, advanced cancer. Twenty-one patients with MMR deficient tumors were enrolled onto the non-CRC cohort with an additional 50 patient expansion underway. The pembrolizumab dose is 10mg/kg intravenously every 2 weeks. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be reported in at least the first 17 patients with non-CRC gastrointestinal (GI) cancers. Results: As of September 18, 2015, 17 patients with non-CRC GI cancers have been enrolled on the protocol with additional patients identified. The diseases represented are ampullary (N=4), pancreas (N=4), biliary (N=3), small bowel (N=3), and gastric (N=3) cancers. For the 10 evaluable patients at the time of abstract admission, ORR is 50 % (N=5/10), disease control rate is 70% (N=7/10), OS is 21 months and the median duration of response (range 5.5-17+ months) and PFS have not been reached. The median follow up duration is 7.6 months. Conclusions: PD-1 blockade shows promising activity in mismatch repair deficient GI cancers. Clinical trial information: NCT01876511.


  • Colorectal Clinical Trials: What is on the Horizon?

    by Daniel H Ahn, Richard M Goldberg

    Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.


  • Open Access

    Advances in Colorectal and Anal Cancer Treatment Based Upon Selected ASCO 2016 Presentations—Advances in Immunotherapy and Considering the Site of the Primary Tumor in Treatment Decisions

    by Richard M Goldberg

    The colorectal cancer oral session of the ASCO 2016 meeting had two themes: immunotherapy and tumor “sidedness”. PD-1 inhibitors were active in patients with anal cancer, with tumors exhibiting microsatellite instability combined with an antibody targeting CTLA-4, and with a Mek inhibitor in microsatellite stable tumors. Three abstracts noted an overall survival advantage for left over right sided colorectal tumors and cetuximab combined with chemotherapy appeared to benefit patients with left but not right sided tumors.

  • Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?

    by Richard M. Goldberg

    Remarkable strides have been made in the past 10–15 years in identifying the molecular events that drive cancer. With an enormous amount of new data, including those from The Cancer Genome Atlas Project, therapies are increasingly being developed and tested in clinical trials specifically designed to target some of these molecular events. Often, molecular signatures have become more important than the histologic features in making treatment choices. The success rate of these therapies depends on many factors but, perhaps most importantly, on patient selection according to the genetic analysis results of their individual tumors.